<div id="readability-page-1">Securian Asset Management Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 43.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 154,605 shares of the biopharmaceutical company's stock after selling 119,974 shares during the period. Securian Asset Management Inc.'s holdings in Pfizer were worth $3,850,000 as of its most recent SEC filing.<ul><li>5 High-Yield Stocks to Shield Your Portfolio From the Storm</li></ul>Other institutional investors also recently added to or reduced their stakes in the company. Horizon Financial Services LLC increased its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 645 shares during the period. YANKCOM Partnership bought a new position in Pfizer in the 4th quarter worth approximately $28,000. Grey Fox Wealth Advisors LLC bought a new position in Pfizer in the 3rd quarter worth approximately $29,000. Darwin Wealth Management LLC bought a new position in Pfizer in the 2nd quarter worth approximately $32,000. Finally, Torren Management LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $34,000. 68.36% of the stock is owned by institutional investors. <h2>Pfizer News Summary</h2>Here are the key news stories impacting Pfizer this week:<ul> <li>Positive Sentiment: Scotiabank initiated a Buy view on Pfizer, adding to recent analyst confidence in the stock. Pfizer (PFE) Receives a Buy from Scotiabank</li> <li>Positive Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Pfizer, reinforcing expectations that earnings remain stable and in line with consensus. </li> <li>Positive Sentiment: Recent coverage highlighted Pfizer’s Q1 beat, better-than-expected sales, and progress in its oncology pipeline, suggesting the company’s newer drugs are becoming more important to the investment story. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story</li> <li>Positive Sentiment: Pfizer’s dividend remains a major draw for income investors, and a recent article argued that the high yield is still supported by management’s execution and cash flow. Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics</li> <li>Neutral Sentiment: Pfizer is continuing to advance a new Phase 1 cancer trial, which signals ongoing investment in oncology but is still too early to materially change near-term financial results. Pfizer’s New Phase 1 Cancer Trial Signals Fresh Oncology Push for PFE Investors</li> <li>Neutral Sentiment: Pfizer was also mentioned in a cancer-care industry recognition announcement, but the item is mostly reputational and unlikely to move the stock on its own.</li> <li>Negative Sentiment: Pfizer halted an early-stage cancer study, and investors may view the termination as a small setback for its oncology pipeline, even if the financial impact is limited. Pfizer Terminates Early-Stage Cancer Trial: What It Means for PFE Investors</li> <li>Negative Sentiment: Pfizer ended another early-stage lymphoma combination trial, which adds to concerns that some pipeline programs may not advance as hoped. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside</li> </ul><h2>Pfizer Price Performance</h2><ul><li>Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most</li></ul>Shares of PFE stock opened at $25.65 on Monday. The stock's fifty day simple moving average is $27.14 and its 200 day simple moving average is $26.16. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a market cap of $146.17 billion, a price-to-earnings ratio of 19.58 and a beta of 0.35. Pfizer Inc. has a one year low of $21.97 and a one year high of $28.75. Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year. <h2>Pfizer Announces Dividend</h2><ul><li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li></ul>The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer's payout ratio is currently 131.30%. <h2>Analysts Set New Price Targets</h2>Several analysts have recently weighed in on PFE shares. Cantor Fitzgerald reissued a &#34;neutral&#34; rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a &#34;neutral&#34; rating on the stock in a report on Thursday, April 9th. Barclays started coverage on Pfizer in a report on Thursday, February 19th. They set an &#34;underweight&#34; rating and a $25.00 price objective on the stock. Wall Street Zen raised Pfizer from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday. Finally, UBS Group lifted their price objective on Pfizer from $25.00 to $27.00 and gave the stock a &#34;neutral&#34; rating in a report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average price target of $28.74.Read Our Latest Stock Report on Pfizer<h2>About Pfizer</h2> (Free Report)Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas. Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.<h2>See Also</h2><ul><li>Five stocks we like better than Pfizer</li><li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li><li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li><li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li><li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li></ul>Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).<img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Pfizer Right Now?</h2>Before you consider Pfizer, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

TBXU

Securian Asset Management Inc. has reduced its holdings in Pfizer Inc. by 43.7%, selling 119,974 shares during the 4th quarter, leaving it with 154,605 shares valued at $3.85 million. Other institutional investors have also adjusted their stakes in Pfizer. Recent analyst coverage has been positive, with Scotiabank initiating a Buy rating and Erste Group raising FY2026 EPS estimates. However, Pfizer faced setbacks with the termination of early-stage cancer trials, which may impact investor sentiment. The stock opened at $25.65, with a market cap of $146.17 billion and a P/E ratio of 19.58.

- Securian Asset Management Inc. reduced its holdings in Pfizer Inc. by 43.7% during the 4th quarter, owning 154,605 shares worth $3,850,000 after selling 119,974 shares.  
- Various institutional investors have adjusted their stakes in Pfizer, with Horizon Financial Services LLC increasing its position by 174.8% during the same period.  
- Analysts generally maintain a "Hold" rating on Pfizer, with a mixture of positive and negative sentiments regarding recent performance and ongoing trials affecting the stock's outlook.

Market Beat

Pfizer

Invesco Biotechnology & Genome ETF

Direxion Daily Biotech Top 5 Bull 2X ETF

VG Health

iShares US Pharma

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

SPDR S&P Biotech

ALPS Medical Breakthrough

Securian Asset Management Inc. Sells 119,974 Shares of Pfizer Inc. $PFE